Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Thermo Fisher Scientific Plans Mebane, North Carolina, Production Complex

12/02/2021
Thermo Fisher Scientific plans to build a state-of-the-art manufacturing facility in Mebane, North Carolina. The project is expected to create 150-200 jobs.

The site is part of a co-investment with the U.S. government, a $192.5 million contract in coordination with the U.S. Department of Health and Human Services to ensure domestic supply of critically needed laboratory pipette tips.

"The new manufacturing facility will help the U.S. meet future demand surges for vital laboratory products while bringing more high-quality jobs to North Carolina," said Mark Stevenson, executive vice president and chief operating officer, Thermo Fisher Scientific. "With its strategic geographic location and proximity to a diverse talent base, Mebane is an ideal location for this new facility."

Thermo Fisher currently employs approximately 4,000 colleagues across seven sites in North Carolina, including a center of excellence for laboratory equipment in Asheville, three life sciences and chemical manufacturing sites in Durham, pharmaceutical manufacturing sites in Greenville and High Point, and a Raleigh distribution center.

"North Carolina offers companies like Thermo Fisher a diverse life science workforce and world-class universities and community colleges that keep building that workforce day after day," said North Carolina Commerce Secretary Machelle Baker Sanders. "In North Carolina, we understand that to attract and help companies compete in today's global economy, our state must be first in talent, and we're strongly committed to meeting that goal."

According to company officials, the investment in Mebane is part of a larger strategy to build flexible and redundant production capacity in the U.S. and across key regions globally. Increased output from recent site expansions is helping meet ongoing demand for COVID-19-related consumables, including plastics used to collect samples and transport them to labs, as well as for vital equipment, such as single-use technologies (SUT), used to accelerate production and allow flexibility for both COVID and non-COVID vaccines and therapies.

Exclusive Research